Comparative Study of Compliance and Factors Affecting Compliance among Commonly Used Drugs in Deep Vein Thrombosis Patients
Sajid Ali *
Department of Pharmacy, Shah Abdul Latif University (SALU), Khairpur, Sindh, Pakistan.
Kheraj Mal
National Institute of Cardiovascular Diseases (NICVD), Sukkur, Sindh, Pakistan.
Jaghat Ram
National Institute of Cardiovascular Diseases (NICVD) Satellite Center, Larkana, Sindh, Pakistan.
Rukhsana Malik
Department of Pharmacology, People’s University of Medical and Health Sciences for Women (PUMHSW), Nawabshah, Sindh, Pakistan.
Muhammad Aslam Abbassi
Department of Pharmaceutics, Faculty of Pharmacy, University of Sindh, Jamshoro, Sindh, Pakistan.
Qararo Shah
Shaheed Mohtarma Benazir Bhutto Medical University (SMBBMU), Larkana, Sindh, Pakistan.
Ufn Sahrish
Chandka Medical College at Shaheed Mohtarma Benazir Bhutto Medical University (SMBBMU), Larkana, Sindh, Pakistan.
*Author to whom correspondence should be addressed.
Abstract
Objectives: The objective of current research was to identify the compliance of antithrombotic drug (heparin, warfarin and Rivaroxaban) and factors of non-compliance associated with heparin, warfarin and rivaroxaban.
Methodology: A cross-sectional, observational study was conducted on patients suffering from Deep Vein Thrombosis (DVT) at government teaching hospital of Larkana. 348 DVT patients were selected by using online sample calculator software. Data was collected by using pre validated questionnaire after taking patient consent; finally the data was analyzed with statistical package of social sciences (SPSS) version 25.
Results: The compliance with rivaroxaban was present in 103 (80.5%) patients followed by heparin drug compliance in 95 (74.2%) DVT patients and warfarin drug compliance in 98 (76.6%) DVT patients. Non-compliance factors with rivaroxaban were; cost in 4 (16.0%) patients, polypharmacy in 6 (24.0%) patients, side effects in 4 (16.0%) patients and prolong therapy in 11 (44.0%) patients. Non-compliance factors with heparin were; monitoring in 13 (39.4%) patients, diet restriction in 6 (18.2%) patients, injectable in 10 (30.3%) patients and ADR in 4 (12.1%) patients. Non-compliance factors with warfarin were; cost in 4 (13.3%) patients, polypharmacy in 8 (26.7%) patients, prolong therapy in 5 (16.7%) patients and ADR in 13 (43.3%) patients.
Conclusion: This study concludes that rate of drug compliance was high in patients of DVT with rivaroxaban followed by warfarin and heparin, whereas long duration of therapy, polypharmacy, side effects of therapy, cost of therapy, continuous monitoring, injectables, diet restrictions and ADRs of therapy were the most commonly reported factors of non-compliance.
Keywords: Deep venous thrombosis, heparin, warfarin, rivaroxaban